Efficacy and Safety Trial of Verubecestat (MK-8931) in Participants With Prodromal Alzheimer's Disease (MK-8931-019)

NCT01953601 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

1454

Enrollment

INDUSTRY

Sponsor class

Conditions

Amnestic Mild Cognitive Impairment
Alzheimer's Disease
Prodromal Alzheimer's Disease

Interventions

DRUG: Verubecestat 12 mg (Parts 1 and 2)
DRUG: Verubecestat 40 mg (Parts 1 and 2)
OTHER: Placebo (Part 1)

Sponsor

Merck Sharp & Dohme LLC